Listen to the article
Federal Prosecutors Recover Over $50 Million in Pfizer Kickback Scheme Involving Migraine Drug
Federal prosecutors have recovered more than $68 million through settlement agreements and enforcement actions in 2025, with the largest portion coming from a major pharmaceutical kickback case, according to an announcement from the U.S. Attorney’s Office for the Western District of New York.
U.S. Attorney Michael DiGiacomo revealed that Pfizer, on behalf of its subsidiary Biohaven, paid more than $50 million to settle allegations that Biohaven provided kickbacks to healthcare providers who prescribed the migraine medication Nurtec. The settlement represents one of the largest healthcare fraud recoveries in the district’s recent history.
Nurtec, known generically as rimegepant, is a calcitonin gene-related peptide (CGRP) receptor antagonist that has gained significant market share in the competitive migraine treatment sector since its approval. The medication has been heavily marketed as an alternative to traditional triptan therapies.
The case highlights ongoing scrutiny of pharmaceutical marketing practices, particularly arrangements between drug manufacturers and prescribing physicians. Under federal anti-kickback statutes, pharmaceutical companies are prohibited from offering financial incentives to healthcare providers to influence prescribing decisions.
“The settlements and recoveries achieved by the ACE Unit in 2025 demonstrate this Office’s commitment to protecting taxpayer money,” DiGiacomo stated. “My office will continue to aggressively root out fraud, waste, and abuse involving government programs and hold those responsible accountable.”
The Pfizer/Biohaven case was among several significant recoveries announced by the office’s Affirmative Civil Enforcement (ACE) Unit, which serves as the civil arm of the U.S. Attorney’s Office. The unit investigates and pursues claims under the Federal False Claims Act, which allows the government to recover both the actual loss amount and additional damages.
Beyond the pharmaceutical industry case, the office settled five matters involving Paycheck Protection Program (PPP) fraud, resulting in the recovery of more than $10 million. The PPP was established during the COVID-19 pandemic to provide financial assistance to businesses, but has been plagued by instances of fraud since its inception.
The ACE Unit also resolved several non-False Claims Act matters, including cases involving self-disclosed overpayments to federal healthcare programs and claims related to the federally funded Railroad Retirement Board pension program.
Many of the successful enforcement actions stemmed from information provided by whistleblowers through the False Claims Act’s qui tam provision, which allows individuals with knowledge of fraud against government programs to file lawsuits on behalf of the government and potentially share in any financial recovery.
The pharmaceutical industry has faced increasing scrutiny in recent years over marketing practices, with several major settlements related to kickback schemes. These arrangements can not only violate federal law but also potentially influence medical decisions, raising concerns about patient care and healthcare costs.
The Pfizer settlement adds to a growing list of major pharmaceutical companies that have faced significant penalties for kickback-related violations. In the highly competitive migraine treatment market, where newer CGRP inhibitors like Nurtec compete for market share, proper marketing practices are under particular scrutiny.
Federal authorities encourage individuals with information about potential fraud to contact appropriate agencies. Healthcare fraud information can be reported to the HHS Office of Inspector General or the FBI, while COVID-19-related fraud can be reported through the Department of Justice’s National Center for Disaster Fraud.
The Western District of New York’s enforcement efforts reflect a broader nationwide push to combat healthcare fraud, which costs taxpayers billions annually and undermines the integrity of federal healthcare programs.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
12 Comments
Over $68 million in recoveries from various fraud and waste schemes – that’s quite an impressive result. It’s important work to safeguard public funds.
Indeed. Rooting out these types of schemes helps ensure that healthcare resources are used appropriately and efficiently.
The details on the Nurtec kickback case are quite troubling. I hope this sends a clear message to the industry about the consequences of such unethical practices.
Agreed. Significant financial penalties can be an effective deterrent, but rigorous monitoring and enforcement are also crucial going forward.
Interesting to see the authorities cracking down on pharmaceutical kickbacks. It’s important to maintain transparency and integrity in the healthcare industry.
Agreed. Kickbacks can lead to overutilization of certain drugs and inflate healthcare costs. Rigorous enforcement is crucial.
Pharmaceutical marketing tactics are always a concern. It’s good to see authorities taking strong action against improper incentive schemes like this one.
Absolutely. Patient welfare should be the top priority, not corporate profits. Strict oversight is necessary to protect public health.
Pharmaceutical kickbacks are a serious issue that can undermine patient care and drive up healthcare costs. Kudos to the prosecutors for their diligence.
Absolutely. Maintaining high ethical standards in the industry should be a top priority to protect both patients and the public interest.
Over $50 million recovered from a single kickback scheme involving a migraine drug – that’s a huge amount. Kudos to the prosecutors for their diligence.
Indeed, the scale of this case highlights just how pervasive these practices can be in the pharmaceutical industry. Ongoing vigilance is required.